Search
Cardiolipin Biosynthesis CL(11:0/i-20:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0188841MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(13:0/i-20:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0198685MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(15:0/i-20:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0205576MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(a-13:0/20:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0245993MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(a-15:0/20:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0246071MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(i-14:0/20:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0246313MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(8:0/i-20:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0475570MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigationalInavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers. … [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605]
Synonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalThe FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.
rCFP-10
go.drugbank.com/drugs/DB21907ApprovedrCFP-10 is a recombinant culture filtrate protein of _Mycobacterium tuberculosis_ used as an ingredient in the diagnostic agent SIILTIBCY along with [rdESAT-6].[L53638]